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Abstract
Background: Onchocerciasis is a leading cause of blindness worldwide, hence elimination of the
infection is an important health priority. Community-based treatment programs with ivermectin
form the basis of control programs for the disease in Latin America. The long-term administration
of ivermectin could eliminate Onchocerca volvulus infection from endemic areas in Latin America.
Methods: A strategy of annual to twice-annual treatments with ivermectin has been used for
onchocerciasis in endemic communities in Ecuador for up to 14 years. The impact of ivermectin
treatment on ocular morbidity, and O. volvulus infection and transmission was monitored in seven
sentinel communities.
Results: Over the period 1990–2003, high rates of treatment coverage of the eligible population
were maintained in endemic communities (mean 85.2% per treatment round). Ivermectin reduced
the prevalence of anterior segment disease of the eye to 0% in sentinel communities and had a
major impact on the prevalence and transmission of infection, with possible elimination of infection
in some foci.
Conclusion:  The distribution of ivermectin in endemic communities in Ecuador might have
eliminated ocular morbidity and significant progress has been made towards elimination of the
infection. A strategy of more frequent treatments with ivermectin may be required in communities
where the infection persists to achieve the objective of elimination of the infection from Ecuador.
The elimination of the infection from an endemic country in Latin America would be a major public
health achievement and could stimulate the implementation of elimination strategies in other
endemic countries.
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Background
Onchocerciasis is an important blindness-causing disease
resulting from infection by the filarial parasite Onchocerca
volvulus, transmitted by Simulium blackflies. An estimated
18 million persons are infected worldwide [1], and
approximately 770000 are blind or visually impaired as a
consequence of the infection [1]. The infection also causes
severe and troublesome skin disease [2] and is associated
directly with increased mortality [3].
Ivermectin (Mectizan®) is an oral microfilaricidal drug
that is safe and effective for mass treatment of onchocer-
ciasis [4] and is provided free to endemic countries by
Merck & Co. The Onchocerciasis Elimination Program for
the Americas (OEPA) has coordinated the distribution of
ivermectin since 1991 in the six endemic countries in
Latin America (Brazil, Colombia, Ecuador, Guatemala,
Mexico and Venezuela) with two principal goals: to elim-
inate morbidity caused by onchocerciasis by 2007 and to
eliminate the infection where possible using a strategy of
mass treatment of endemic communities with ivermectin
[5].
Elimination is a high priority to prevent new morbidity, to
allow the reallocation of limited health and financial
resources to other health priorities, and because of the
potential for the development of parasite resistance to
ivermectin in the long term [6]. The development of
resistance to ivermectin by O. volvulus is a serious concern
because there are no safe or practical alternative treat-
ments currently available for mass distribution in human
populations. It has been suggested that the infection
could be eliminated from the Americas, through twice-
annual treatments with ivermectin to greater than 85% of
the eligible population at risk for onchocerciasis over a
period of 10–15 years, via the interruption of the trans-
mission of infection and death of adult parasites by senes-
cence [7].
In Ecuador, the National Program for the Elimination of
Onchocerciasis has pursued a program of mass treatments
with ivermectin in endemic communities over the past 14
years (1990–2003) and has achieved high rates of cover-
age. The Ecuadorian Program provides an important
model to evaluate whether elimination of O. volvulus
infection is a realistic aim for an endemic country in the
Americas using an ivermectin-based treatment strategy.
Methods
Study area
The province of Esmeraldas, latitude 1°96'S to 1°43'N
and longitude 78°48'W to 80°9'W, is situated west of the
Andes in North-Western Ecuador [8]. The principal
endemic area of onchocerciasis is located in the District of
Eloy Alfaro (Figure 1). The Santiago basin focus is formed
Geographic locations Figure 1
Geographic locations. (A) Geographic location of endemic 
area for onchocerciasis in Ecuador. The endemic focus is 
located in the Northern coastal area of Ecuador adjacent to 
Colombia. There are a total of 119 endemic communities for 
onchocerciasis located in Esmeraldas Province (117 commu-
nities) and Pichincha Province (two communities). The 
endemic area consists of hyperendemic (red circles), mes-
oendemic (yellow squares), and hypoendemic (green trian-
gles) communities. There are six satellite foci (Tuluví, Verde, 
Viche, Canandé, Sucio and Santo Domingo de Los Colora-
dos). The areas in green represent the foci of onchocerciasis. 
(B) Geographic location of the seven sentinel communities in 
the District of Eloy Alfaro in Esmeraldas Province. Hyperen-
demic (red circles), and mesoendemic (yellow square) senti-
nel communities are shown. The areas in green represent the 
foci of onchocerciasis.BMC Medicine 2007, 5:9 http://www.biomedcentral.com/1741-7015/5/9
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by the union of three rivers, the Río Santiago, Río Cayapas
and Río Onzole and their respective tributaries, each
forming a separate sub-focus. Satellite endemic foci are
located on separate rivers caused by the migration of
microfilariae-positive individuals from the principal
endemic focus [9]. Five satellite foci are found in the prov-
ince of Esmeraldas, located on the rivers Río Canandé, Río
Verde, Río Viche, Río Sucio, and Río Tuluví. A small focus
is also found in the neighboring province of Pichincha
near Santo Domingo de los Colorados. A total of 119
communities are considered endemic for onchocerciasis.
Ivermectin distribution
The National Program for Onchocerciasis Elimination in
Ecuador chose to use ivermectin as the disease control
strategy through mass drug distribution in endemic com-
munities since 1990. Before 1990, control relied largely
on periodic nodulectomy campaigns in the endemic areas
[10]. The distribution of ivermectin was started in
endemic communities over the period 1990 to 1993
although treatment was delayed in a few until 1997. All
consenting eligible inhabitants (approximately 19420) of
the 119 communities have been treated for up to 14 years
(1990–2003). Eligibility criteria for treatment were:
weight greater than 15 kg, women not pregnant or nursing
infants up to 3 months of age, and free of serious illness
(e.g. active tuberculosis, terminal cancer etc). Ivermectin
is distributed by specially-trained primary health care
workers in each community at a dose of 150 µg/mg using
standard exclusion criteria [11]. The population census is
used as the basis for drug distribution. Health workers are
responsible for health education, updating the census
annually, identifying those not eligible for treatment and
treating all eligible individuals.
Ivermectin has been distributed annually to endemic
communities in the Río Cayapas since 1991–1992 except
for seven communities in the hyperendemic area of the
Río Cayapas sub-focus that received their first mass treat-
ment between 1995 and 1996. A second annual dose of
ivermectin was provided to hyperendemic communities
in the Río Cayapas over the periods 1992–1994 and
1998–2003. A second dose was not given in the years
1995–1997 due to financial restraints on the program and
a decision to fall in line with the strategy of annual treat-
ments adopted by the African Program for Onchocerciasis
Control (APOC) [7]. However, following the finding that
twice-annual treatments could suppress onchocerciasis
transmission in the Santiago sub-focus [11], the strategy
of twice-annual treatments in hyperendemic communi-
ties was reinitiated from 1998. All endemic communities
have been treated twice annually since 2001. The number
of treatments and the start of ivermectin mass distribution
provided to each river sub-focus and the satellite foci
according to endemicity of infection are provided in Table
1.
Sentinel communities
The use of sentinel communities has been recommended
for the in-depth evaluation of ivermectin distribution pro-
grams [1]. To evaluate the impact of mass distribution of
ivermectin, seven communities were selected for periodic
prospective in-depth epidemiological surveys. The seven
sentinel communities were located in the following areas
Table 1: Characteristics of ivermectin mass distribution in the 119 comunities endemic for onchocerciasis in Ecuador
Location/endemicity Ivermectin treatments Mean treatment coverage % (range)
No. of communities Year of first treatment No. treatments Median (range)
Río Cayapas:
Hyperendemic 31 1991–1996* 22 (13–22) 84.8 (49.9–95.3)
Mesoendemic 9 1991 16 (16–16) 86.7 (74.2–97.7)
Hypoendemic 7 1991–1993 16 (14–16) 84.7 (71.0–94.4)
Río Onzole:
Hyperendemic 3 1991–1992 16 (15–17) 84.5 (63.4–98.1)
Mesoendemic 1 1991 16 90.3 (72.7–100)
Hypoendemic 13 1991–1993 15 (15–16) 87.2 68.5–97.2)
Río Santiago:
Hyperendemic 8 1990–1991† 19 (17–19) 90.7 (78.1–98.7)
Mesoendemic 4 1990 18 (17–19) 87.7 (65.4–99.0)
Hypoendemic 23 1990–1991 16 (16–17) 88.9 (81.1–100)
Satelite foci:
Mesoendemic 9 1991–1993 18 (14–19) 83.2 (37.3–97.9)
Hypoendemic 11 1990–1997 13 (11–17) 89.9 (48.7–98.4)
*In the Río Cayapas first treatments with ivermectin were provided in the hyperendemic communities in the following years: 1991 (23 
communities), 1992 (1), 1995 (1), and 1996 (6). †In the Río Santiago first treatments with ivermectin were provided in the hyperendemic 
communities in the following years: 1990 (7 communities) and 1991 (1 community).BMC Medicine 2007, 5:9 http://www.biomedcentral.com/1741-7015/5/9
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of the Santiago basin main focus: (1) hyperendemic area
– Río Santiago: Playa del Oro, Angostura and Guayabal
communities; (2) hyperendemic area – Río Cayapas: Cor-
riente Grande, El Tigre and San Miguel communities; and
(3) mesoendemic area – satellite focus in Río Canandé:
Naranjal de los Chachis community. Sentinel communi-
ties in the principal hyper-endemic sub-foci of the Río
Santiago and Río Cayapas were chosen to evaluate the
potential for reduction in transmission of infection
through ivermectin treatment. A meso-endemic commu-
nity in the Río Canandé was included because of large
changes in prevalence that occurred over the period
1980–1986 and the high infectivity and human bite rates
in this satellite focus [9]. Evaluations were performed
before the start of ivermectin treatment in 1989 and in
2000 and 2004. The period from the last treatment with
ivermectin provided in 2003 to the evaluations performed
in 2004 was approximately 12 months. Parasitological
ophthalmological, and entomological parameters were
evaluated using standardized methodology [12]. Selec-
tion for inclusion in the parasitological and opthalmolog-
ical assessments were: (1) parasitological – all individuals
in the community census aged 1 year or greater, and (2)
ophthalmological – all individuals in the census aged 10
years or greater. The study was approved by the Ethics
Committee of the Hospital Vozandes, Quito, Ecuador.
Informed verbal consent to participate in the study was
obtained through meetings of community elders and the
individual participants.
Prevalence of infection and microfilarial load
Skin snips were taken from both iliac crests using a Stolz
corneoscleral punch and weighed. The biopsies were
placed in micro-well plates with phosphate buffered
saline, and emergent microfilariae were counted micro-
scopically after 24 hours. Microfilarial densities are
expressed as the number of microfilariae per milligram of
skin (mf/mg). Mean microfilarial load (MMFL) was calcu-
lated as the geometric mean of infection intensities of all
members of the community including skin-snip negatives
(i.e. eSum(loge[x+1])/N-1, where x is individual microfilarial
loads and N is the number of individuals examined).
Ophthalmology
Ocular examinations included assessment of visual acuity,
slit lamp examination of the anterior segment, and direct
and indirect ophthalmoscopy of the posterior segment
[13]. All examinations were performed by two experi-
enced ophthalmologists (JR and RP) using the modified
rapid ocular evaluation criteria recommended by the Pan
American Health Organization [14].
Entomology
Simulium blackflies were collected in the seven sentinel
communities during the seasonal period of maximum bit-
ing in 1995 in the sentinel communities of Tigre and San
Miguel and in all sentinel communities in 2000 and 2004.
Standard procedures were followed for blackfly collec-
tions [15]. Blackflies were collected in 99% alcohol and
identified using a taxonomic key of Simulium [16]. O. vol-
vulus DNA was amplified by PCR using primers for the O.
volvulus-specific DNA sequence O-150 [17] in pools of 50
blackflies, and the O. volvulus-specific PCR products were
detected by ELISA as reported previously [17]. The preva-
lence of infection was calculated using the algorithms
contained in Poolscreen 2.0 (The University of Alabama,
Birmingham, Alabama, USA), a statistical program that
estimates the prevalence of infection in the vector popula-
tion based upon the proportion of positive pools [18].
Results
Ivermectin treatments and treatment coverage in all 
endemic communities
The average annual treatment coverage per treatment
round with ivermectin from 1990 to 2003 (total of up to
24 treatments) of eligible individuals in endemic commu-
nities receiving treatment, based on a yearly updated cen-
sus, was 85.2% (range 54.9–97.9%). Between 1990 and
2000, annual mass distribution of ivermectin was pro-
vided in endemic communities except for seven commu-
nities in the Río Cayapas where treatment was delayed
until 1995–1996 as described in the Methods section.
From 2001, all 119 endemic communities were treated
twice annually with ivermectin. Between 1990 and the
end of 2003, prior to the evaluations in 2004, endemic
communities received a range of 11–22 total treatments
with ivermectin (Table 1). Average coverage per treatment
round of ivermectin was high (>83%) in all endemic foci
(Table 1).
Characteristics of sentinel communities
The population eligible for treatment with ivermectin,
number of mass treatments, treatment strategy by year
(single vs. twice annual), and treatment coverage are
shown in Table 2. The age and sex distribution of the sen-
tinel communities were similar between the three surveys.
The number of treatment rounds was not uniform for all
study communities. Corriente Grande, Río Cayapas,
received a total of 21 ivermectin treatments while El Tigre
and San Miguel on the same river received 13 treatments.
The average treatment coverage was ≥ 85% except for
Guayabal (Río Santiago) and Naranjal (Río Canandé).
Impact of ivermectin: O. volvulus infection prevalence 
and MMFL
The number of subjects aged 1 year or greater in the 2004
census in each sentinel community and the proportions
examined (brackets) in the 2004 survey were: Corriente
Grande, 212 (83.0%); El Tigre, 143 (67.8%); San Miguel,
197 (79.2%); Playa de Oro, 267 (71.9%); Guayabal, 114
(65.8%); Angostura, 83 (67.5%); and Naranjal, 581
(83.0%). Overall, 77.3% of these 1597 individuals wereBMC Medicine 2007, 5:9 http://www.biomedcentral.com/1741-7015/5/9
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examined. Marked reductions of prevalence of infection
were seen in the sentinel communities over the periods of
mass distribution of ivermectin (Table 3). In the 2004 sur-
vey, all persons examined in four of the sentinel commu-
nities were negative for detectable microfilariae in skin
snips, but positive skin snips were detected in all the sen-
tinel communities in the hyperendemic area in the Río
Cayapas where 5 individuals had positive skin snips (Cor-
riente Grande, 1 individual; El Tigre, 2; and San Miguel,
2). Infected individuals had a median age of 46 years
(range 27–49 years) and had received a median of 11 iver-
mectin treatments (range 6–13 treatments). All but one
had onchocercal nodules. A further four skin-snip nega-
tive individuals (median age 15 years [range 8–21] and
median 14 treatments [range 4–17]) developed localized
maculopapular rashes approximately 24 hours after iver-
mectin treatment given immediately after the clinical eval-
uations. No children aged 5 years or less were positive for
microfilariae in skin snips. There were reductions in the
microfilariae densities in all sentinel communities over
the treatment periods (Table 3).
Impact of ivermectin: anterior segment eye lesions
The number of subjects aged 10 years or more (i.e. able to
cooperate fully with the ocular examination) in the 2004
census in each sentinel community and the proportions
examined (brackets) in the 2004 survey were: Corriente
Grande, 132 (93.9%); El Tigre, 87 (83.9%); San Miguel,
129 (86.0%); Playa de Oro, 198 (68.2%); Guayabal, 78
(66.7%); Angostura, 55 (78.2%); and Naranjal, 387
(81.7%). Overall, 80.1% of these 1066 individuals were
examined. Data is provided only for the early anterior seg-
ment changes (punctate keratitis and the presence of
microfilariae in the anterior chamber) that are considered
to be specific for O. volvulus infection, resolve completely
after effective chemotherapy and provide a strong indica-
tion for reduction in ocular morbidity and the risk of later
severe ocular disease (e.g. iridocyclitis, sclerosing keratitis,
chorioretinopathy and optic atrophy) after ivermectin
treatment. The prevalence of punctate keratitis before
treatment and in the surveys conducted in 2000 and 2004
is shown in Table 4. By 2000, there were reductions in the
prevalence of punctate keratitis in all sentinel communi-
ties and no evidence of punctate keratitis was found in
Angostura in the Río Santiago. No evidence of punctate
keratitis was observed in the 2004 survey in any of the sen-
tinel communities. No microfilariae in the anterior cham-
ber were observed in any of the sentinel communities in
the 2000 and 2004 surveys.
Impact of ivermectin: transmission of O. volvulus infection
All anthropophilic biting blackflies in the seven sentinel
communities were identified as S. exiguum or S. quadrivit-
tatum. The predominant species collected in the sentinel
communities in the Río Santiago was S. quadrivittatum
(22.1% S. exiguum vs. 77.9% S. quadrivittatum in 2000;
11.5% S. exiguum vs. 88.5% S. quadrivittatum in 2004), in
contrast to the Río Cayapas where S. exiguum predomi-
nated (76.2% S. exiguum vs. 23.8% S. quadrivittatum in
2000; 78.5% S. exiguum vs. 21.5% S. quadrivittatum in
2004). In Naranjal in the Río Canandé, S. exiguum was the
principal human biting species (2000, 99.0% S. exiguum
vs. 1.0% S. quadrivittatum in 2000; 99.2% S. exiguum vs.
0.8% S. quadrivittatum in 2004). The blackflies were ana-
lyzed for the presence of O. volvulus DNA (O-150) by
PCR-ELISA (2009 pools analyzed for 2000 and 1845
Table 2: Characteristics of the seven sentinel communities in Esmeraldas Province, Ecuador selected to evaluate the impact of 
ivermectin treatment on O. volvulus infection
Community Location/endemicity Ivermectin treatments Mean treatment coverage % (range)
Treatment eligible* Annual Twice annual Treatments
Corriente Río Cayapas/Hyperendemic 173 1991- 1995 1992–1994 21 86.1 (19.1–99.4)
Grande 1997 1998–1999
2000 2001–2003
El Tigre Río Cayapas/Hyperendemic 121 1996–1997 1998–1999 13 94.4 (82.3–100)
2000 2001–2003
San Miguel Río Cayapas/Hyperendemic 175 1996–1997 1998–1999 13 91.8 (85.7–97.9)
2000 2001–2003
Playa de Río Santiago/Hyperendemic 236 1990 1991–1992 19 93.3 (81.8–100)
Oro 1993–2000 2001–2003
Guayabal Río Santiago/Hyperendemic 101 1990 1991–1992 19 84.7 (64.4–100)
1993–2000 2001–2003
Angostura Río Santiago/Hyperendemic 72 1992–2000 1991 19 89.4 (75.9–100)
2001–2003
Naranjal Río Canandé/Mesoendemic 491 1994–2000 1991–1993 19 83.9 (48.5–96)
2001–2003
*Data from 2004 census.BMC Medicine 2007, 5:9 http://www.biomedcentral.com/1741-7015/5/9
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pools for 2004). Infection rates per 10000 flies are shown
in Table 5. No evidence of infection of Simulium blackflies
was detected in the three sentinel communities in the Río
Santiago in 2000 and 2004. In the communities of Corri-
ente Grande (Río Cayapas) and Naranjal (Río Canandé),
blackfly infection rates declined to 0 over the period
2000–2004. However, blackfly infections were detected
during both surveys in the communities of El Tigre and
San Miguel in the Río Cayapas. S. exiguum appeared to be
the most important vector during both surveys and O. vol-
vulus infection in S. quadrivittatum was detected only in
Corriente Grande in 2000 but in no other sentinel com-
munity in 2000 or 2004.
Discussion
The National Program for Onchocerciasis Elimination in
Ecuador has used the phased introduction of mass distri-
bution of ivermectin in endemic communities to control
onchocerciasis as a public health problem since 1990. The
findings of the in-depth surveys conducted in 2000 and
2004 provide some evidence that the infection has been
eliminated in the sentinel communities in the Río San-
tiago and Río Canandé. Because of the high coverage rates
achieved, it is possible that O. volvulus infection has been
eliminated from the Río Santiago sub-focus and all satel-
lite foci including the Río Canandé sub-focus. However,
O. volvulus infection is still active in the hyperendemic
sub-focus of the Río Cayapas as demonstrated by the pres-
ence of individuals with dermal microfilariae and infected
Simulium blackflies.
Unlike foci of onchocerciasis in Africa, the foci in the
Americas are geographically well defined and are amena-
ble to focused attack that, theoretically, could lead to
elimination of the infection from the continent. With this
in mind, The PanAmerican Health Organization in 1991
called for the elimination of all morbidity from onchocer-
ciasis in the Americas and where possible suppression of
transmission by 2007 [5,7].
The rationale for the current ivermectin control strategy is
derived from studies conducted in Guatemala that indi-
cated that twice-annual distribution of ivermectin to all
eligible persons could suppress transmission [19,20], and
the results of simulation studies with a mathematical
model that indicated that suppression of transmission
Table 4: Changes in the prevalence of ocular onchocerciasis in the sentinel communities
Sentinel 
community
Presence of punctate keratitis (PK, %) Presence of microfilariae in the anterior chamber (MfAC, %)
1989 2000 2004 1989 2000 2004
Corriente Grande 41.7 1.2 0 50.5 0 0
El Tigre 36.6 1.6 0 27.3 0 0
San Miguel 50.0 4.7 0 50.0 0 0
Playa del Oro 48.8 5.1 0 6.0 0 0
G u a y a b a l1 4 . 3 1 . 5 0000
Angostura 21.4 0 0 14.3 0 0
N a r a n j a l 0 0 . 9 0000
The prevalence of ocular onchocerciasis of the anterior segment is provided by punctate keratitis (PK) and presence of microfilariae in the anterior 
chamber (MfAC).
Table 3: Changes in the epidemiology of O. volvulus infection in the sentinel communities
Community 1989 survey 2000 survey 2004 survey
Prevalence (%) MMFL Prevalence (%) MMFL Prevalence (%) MMFL
Corriente Grande 96.3 34.8 4.8 0.045 0.6 0.003
El Tigre 94.2 59.3 14.0 0.131 2.1 0.007
San Miguel 96.3 57.4 5.1 0.582 1.3 0.007
P l a y a  d e l  O r o 6 6 . 6 2 3 . 6 0000
G u a y a b a l6 3 . 6 2 8 . 4 0000
A n g o s t u r a 8 0 . 6 3 4 . 7 0000
Naranjal 53.3 21.2 0.3 0.001 0 0
The prevalence of infection and microfilarial load with O. volvulus in the sentinel communities is shown. Surveys were conducted in the seven 
sentinel communities before ivermectin treatment in 1989 and in 2000 and 2004 after the start of treatment. MMFL, Mean Microfilarial Load 
(geometric mean mf/mg  skin).BMC Medicine 2007, 5:9 http://www.biomedcentral.com/1741-7015/5/9
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could be achieved by treatment of at least 85% of the eli-
gible population [7]. If suppression of transmission can
be maintained in an isolated focus for the reproductive
life span of adult females, estimated at 13–14 years [21],
the adult parasite population would die by senescence
[22] and the infection would be eliminated.
We have demonstrated previously that an operational
program based on ivermectin distribution twice annually
over a period of 5 years in the Río Santiago sub-focus
appeared to completely suppress O. volvulus transmission
[11]. We have now extended these findings to show that
transmission of O. volvulus in the Río Santiago might have
been interrupted for at least 10 years (1995–2004). There
is no evidence of new onchocercal ocular morbidity in the
Río Santiago and dermal microfilariae have been absent
in the three sentinel communities since 1996 [11]. Fur-
ther, studies to detect IgG4 antibodies against the O. vol-
vulus antigen OV16 using immunochromatic cards that
are highly sensitive and specific for O. volvulus infection
[23] were negative in 112 children aged less than 11 years
in 2001 (i.e. children born since 1990 when the first dose
of ivermectin was administered; Rumbea Guzman et al,
unpublished data) providing further evidence for an inter-
ruption of transmission. These data together indicate that
O. volvulus infection, after at least 13 years of continuous
annual or twice-annual mass treatments with ivermectin,
has now been eliminated from the Río Santiago sub-
focus.
O. volvulus infection remains active in the hyperendemic
communities in the Río Cayapas. Individuals with dermal
microfilariae were detected in three sentinel communities
(total of 5 individuals) during the 2004 survey and
infected blackflies were detected in two sentinel commu-
nities. Two of the three communities had received fewer
ivermectin treatments than other sentinel communities
having started to receive treatment in 1996 (Table 2).
Microfilariae positive individuals were aged greater than
25 years and tended to have evidence of onchocercal nod-
ules (4/5 individuals). The use of skin snips to detect O.
volvulus infection in humans is relatively insensitive and it
is likely that there is a larger reservoir of active infection in
these communities than suggested by the skin snip results.
The latter is supported by the finding of a further four
individuals in the hyperendemic sentinel communities in
the Río Cayapas that had negative skin tests for microfilar-
iae but probable microfilaricidal skin reactions after iver-
mectin at the time of the 2004 survey. It is not clear how
active is infection transmission because a serological study
using the OV16 immunochromatic cards conducted in
2001 showed 2.1% (3/145) of subjects aged 0–5 years to
have evidence of specific antibodies (Rumbea Guzman et
al, unpublished data) although no children in this age
range had positive skin snips for microfilariae. Although
infection remains present, there was no evidence of new
onchocercal ocular lesions in any of the sentinel commu-
nities in the Río Cayapas indicating that ocular onchocer-
ciasis might have been eliminated as a public health
problem.
All of the hyperendemic communities in the Río Cayapas
have received at least 5 years of twice-annual treatments
with ivermectin (Table 1) and the finding of active infec-
tion is in contrast to our previous findings of the possible
complete suppression of infection in the Río Santiago
after 5 years of twice-annual treatments [11] indicating
possible differences in the minimum effective duration of
ivermectin mass treatments required to suppress transmis-
sion between the two infection sub-foci. There are three
possible explanations for this difference: (1) the predom-
inant vector in the Río Cayapas sentinel communities, S.
exiguum, has a higher vectorial capacity than S. quadrivit-
tatum that predominates in the Río Santiago [24,25]; (2)
the same infected individuals might refuse treatment
repeatedly, or are ineligible for long periods (e.g. through
repeated pregnancies), and remain an active source of
transmission of O. volvulus or temporary migrations of
Table 5: Changes in infection rates with O. volvulus in blackflies in the sentinel communities
Sentinel community 1995 2000 2004
Blackflies analysed 
(N)
Infection rate Blackflies analysed (N) Infection rate Blackflies analysed (N) Infection rate
Corriente Grande NP NP 23500 2.1 (0.7–5.0) 12700 0
El Tigre 2550 72.7 (42.0–116.0) 17000 9.0 (4.5–16.1) 10100 6.0 (2.05–13.3)
San Miguel 3550 65.0 (39.0–101.0) 9600 1.1 (0.03–6.4) 12500 0.8 (0.02–4.1)
Playa de Oro NP NP 10250 0 9500 0
Guayabal NP NP 9950 0 10000 0
Angostura NP NP 9700 0 11400 0
Naranjal NP NP 20450 0.5 (0.01–2.8) 26050 0
Infection rates (number of flies infected per 10000 flies) with O. volvulus among Simulium blackflies collected before the start of ivermectin 
distribution (1995), and during the 2000 and 2004 surveys. Infection rates were calculated using Poolscreen 2.0 software. NP – not performed.BMC Medicine 2007, 5:9 http://www.biomedcentral.com/1741-7015/5/9
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infected individuals in and out the Río Cayapas and the
failure of them to receive repeated treatments could main-
tain the infection reservoir (this appears an unlikely expla-
nation as all these individuals found positive had received
significant numbers of ivermectin treatments – 10/13, 6/
13, 12/13, 13/13, and 11/21); and (3) a sub-population
of adult female O. volvulus worms appear to respond
poorly to the fertility suppressant effects of ivermectin,
and this effect is observed after repeated doses [26,27].
The failure to suppress infection in the Río Cayapas might
indicate the need for a change in treatment strategy. Stud-
ies conducted in Cameroon and Guatemala show that
treatment every 3 months with standard doses of ivermec-
tin is safe and well-tolerated and has significant macrofila-
ricidal effects against adult O. volvulus [28,29]. In fact,
histological studies of onchocercal nodules from Ecuador
from individuals with a mean of only 8.2 treatments with
ivermectin have shown dramatic effects on adult female
viability and fertility and also marked reductions in the
frequencies of male worms [30], and provided a histolog-
ical picture similar to that reported in nodules collected in
the Onchocerciasis Control Program area of West Africa
after 9–10 years of vector control [30]. These observations
indicate that the period for which treatment must be
maintained after suppression of infection in a community
is achieved could be less than previously estimated if adult
worms die or cannot maintain sexual reproduction earlier
than previously estimated. It is possible that an intensive
program of increased frequency of ivermectin treatment
(i.e. 3-monthly) in combination with a course of doxycy-
cline that can sterilize adult females worms [31] in skin
test positive individuals and the treatment of repeated
treatment refusers and migrants could yield rapid results
in the suppression of transmission of O. volvulus.
The plan for certification of the elimination of onchocer-
ciasis envisaged by OEPA comprises four phases [15]:
phase I – treatment coverage of greater than 85% of the
population with twice-annual ivermectin treatments for a
period of 2–4 years (or 4–8 rounds of treatment) causing
temporary interruption of transmission; phase II – contin-
ued suppression of O. volvulus with biannual high cover-
age treatments with no blackflies infected with O. volvulus
and no new individuals being infected (i.e. zero incidence
of infection) for the lifespan of the adult female worms
(e.g. 13–14 years [21]); phase III – starting 12–14 years
after the suppression of infection (or 14–18 years after the
start of ivermectin treatments) when all adult females
have died and suppression of infection is no longer
dependent on ivermectin and consists of a 3 year 'surveil-
lance' period of pre-certification during which ivermectin
treatment is suspended; and phase IV – certification of
elimination of the O. volvulus infection.
Our previous observations in the Río Santiago sub-focus
[11] would support the time periods provided for phases
I and II, but to achieve phase I in the hyperendemic area
of the Río Cayapas sub-focus is likely to require much
longer with the current twice-annual treatment strategy. It
is likely that the periods required for each phase will vary
according to the efficiency of the vector species and other
factors unique to each geographic sub-focus (e.g. treat-
ment coverage, migration patterns). Our data indicate
that the Río Santiago sub-focus might be ready for the
third phase of pre-certification. Pre-certification and sus-
pension of ivermectin treatment could be considered also
in Río Onzole sub-focus and satellite foci where annual or
semi-annual treatments have been provided continuously
for at least 13 years.
Before suspension of treatment, a survey of all endemic
communities within each sub-focus should be conducted
to ensure that the findings in the sentinel communities
are generalizeable to non-sentinel communities. These
surveys should include more sensitive diagnostic methods
including the detection of O. volvulus DNA in skin snips
[32] and specific antibodies using the OV16 immuno-
chromatic cards [23,33] to exclude very low-level infec-
tions and histologic analysis of the viability and fertility of
female worms in onchocercal nodules (if present).
Detailed vectors studies might be required to examine the
flight range and dispersal patterns of Simulium blackflies
from communities in the Río Cayapas where transmission
persists because of the potential risk of dispersal of
infected Simulium. Also required will be a study of migra-
tion to determine if there are significant migrations of
potentially infected individuals from the hyperendemic
communities in the Río Cayapas to the Río Santiago and
vice versa. Pre-certification of these foci of infection could
reduce the cost of current control activities by approxi-
mately 75% (from US $250000 to just over US $60000)
and release resources for an intensive elimination strategy
in the Río Cayapas sub-focus.
Conclusion
The National Program for Onchocerciasis Elimination in
Ecuador has pioneered the use of community health
workers to distribute ivermectin and the integration of
ivermectin distribution within primary health care activi-
ties. The diversification of the activities of the control
team and the integration of control within primary health
care services has become increasingly important in main-
taining high rates of coverage with ivermectin as the pub-
lic health threat posed by onchocerciasis is perceived to be
less and less important by the inhabitants of endemic
communities. The data from this study provide evidence
that an operational program in Ecuador might have elim-
inated ocular onchocerciasis as a public health problem
and has made significant progress towards the goal of theBMC Medicine 2007, 5:9 http://www.biomedcentral.com/1741-7015/5/9
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elimination of the infection from Ecuador, and provides a
model control program for the evaluation of the potential
for the elimination of onchocerciasis from the Americas.
The elimination of onchocerciasis from Latin America and
Africa is an important health priority and the data from
the current study provides evidence that an ivermectin-
based treatment program could be a feasible strategy for
the elimination of the infection from other foci of infec-
tion.
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